[Alpha Biz=(Chicago) Reporter Kim Jisun] CJ Bioscience is speeding up the development of new drugs.
CJ Bioscience announced on the 22nd that it will carry out a paid-in capital increase of 65 billion won and 3.23 million 3,830 shares in the form of a general public offering of disqualified shares after shareholder allocation.
The estimated issuance price of new shares is 20,100 won, and the new share allocation date is July 10.
CJ Bioscience explains that the paid-in capital increase is aimed at achieving the goal of developing a new microbiome drug. CJ Bioscience has secured growth engines for new drug development through the US and Korean clinical development of 'CJRB-101' and the acquisition of a new 4D pharma pipeline in March.
CJRB-101 is an immune anticancer target new drug candidate (pipeline) secured by CJ Bioscience and was approved by the US Food and Drug Administration (FDA) earlier this year for Phase 1 and Phase 2 clinical trial plan (IND).
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
